Colon, lung, and liver cancers are among the most prevalent and lethal cancers globally. Despite advancements in treatment, these cancers continue to pose significant challenges due to high mortality rates, late-stage diagnosis, and resistance to conventional therapies. This Research Topic will delve into the identification and therapeutic potential of novel molecular targets in colon and liver cancer, aiming to address these challenges through innovative research and clinical applications. Colon cancer is the third most common cancer worldwide, with an estimated 1.8 million new cases and 881,000 deaths annually. The high mortality rate is primarily due to late-stage diagnosis and metastasis, often resulting in limited treatment options and poor prognosis.
Standard treatments for colon cancer include surgery, chemotherapy, radiation therapy, and targeted therapies. While these treatments have improved survival rates, they are often associated with significant side effects and the development of resistance. Liver cancer is the sixth most common cancer and the third leading cause of cancer-related deaths worldwide, with approximately 905,000 new cases and 830,000 deaths annually. Hepatocellular carcinoma (HCC) is the most prevalent type, often diagnosed at an advanced stage, resulting in limited treatment efficacy and high mortality. Treatment options for liver cancer include surgical resection, liver transplantation, ablation, transarterial chemoembolization (TACE), systemic chemotherapy, and targeted therapies such as sorafenib and Lenvatinib. Despite these options, the prognosis remains poor due to the aggressive nature of the disease and frequent recurrence. The high mortality and prevalence of colon and liver cancers highlight the urgent need for more effective and less toxic treatment options. Novel molecular targets present a promising avenue for addressing these unmet medical needs by providing more precise and personalized therapeutic strategies. Recent advancements in molecular biology and high-throughput technologies have facilitated the discovery of new molecular targets involved in cancer pathogenesis. Understanding these targets' roles in colon and liver cancer progression can lead to the development of innovative therapies that specifically target cancer cells while sparing normal tissues. Targeting novel molecular targets can improve treatment outcomes by overcoming resistance to current therapies, reducing side effects, and enhancing the efficacy of existing treatments. This approach can lead to better patient survival rates and quality of life.
This Research Topic aims to advance the understanding and treatment of colon, lung, and liver cancers by focusing on several key objectives. First, it seeks to identify and characterize novel molecular targets specific to these cancers, elucidating their biological and molecular mechanisms of action. This includes exploring the therapeutic potential and development of new drugs that target these molecules and assessing their efficacy and safety through rigorous preclinical and clinical studies. The Research Topic will also delve into the pathways and interactions involving these novel targets, aiming to understand how their modulation can disrupt cancer progression and enhance patient outcomes. Additionally, it will address mechanisms of resistance to current therapies and investigate how novel targets can overcome these challenges. The development and validation of biomarkers based on these targets for early detection and prognostic assessment will also be a focus. Case studies and clinical trials highlighting the successes and obstacles encountered in targeting these novel targets will be presented, alongside discussions on the real-world application and integration of these therapies into clinical practice. Finally, the Research Topic will identify emerging trends and propose future research directions, aiming to drive breakthroughs in the field of cancer therapy.
This Research Topic welcomes researchers, scientists, and experts to contribute to a collection focused on novel molecular targets in colon, lung, and liver cancers even other types of cancers.
Submissions should address one or more of the following themes:
• Identification and characterization of novel targets specific to colon, lung, and liver cancer cells and understanding the biological and molecular mechanisms driving the expression and function of these targets.
• Therapeutic potential and drug development of new drugs targeting these novel molecules and assessing the efficacy and safety of these novel therapies through preclinical and clinical studies.
• To elucidate the pathways and interactions these novel targets are involved in and understand how targeting these molecules can disrupt cancer progression and survival.
• To identify mechanisms of resistance to current therapies and how novel targets can overcome these challenges.
• To develop and validate biomarkers based on novel molecular targets for early detection of colon and liver cancers.
• To evaluate the prognostic value of these biomarkers in predicting patient outcomes and treatment responses.
• To present case studies and clinical trials that highlight the success and challenges of targeting novel molecular targets in colon, lung, and liver cancer patients.
• To discuss real-world application and integration of these therapies into clinical practice.
• To identify emerging trends in the discovery and application of novel molecular targets and propose future research directions and potential breakthroughs in the field of colon and liver cancer therapy.
We encourage original research articles, reviews, case reports, and technical notes that contribute to the Research Topic "Novel Molecular Targets in Cancer Therapy".
Colon, lung, and liver cancers are among the most prevalent and lethal cancers globally. Despite advancements in treatment, these cancers continue to pose significant challenges due to high mortality rates, late-stage diagnosis, and resistance to conventional therapies. This Research Topic will delve into the identification and therapeutic potential of novel molecular targets in colon and liver cancer, aiming to address these challenges through innovative research and clinical applications. Colon cancer is the third most common cancer worldwide, with an estimated 1.8 million new cases and 881,000 deaths annually. The high mortality rate is primarily due to late-stage diagnosis and metastasis, often resulting in limited treatment options and poor prognosis.
Standard treatments for colon cancer include surgery, chemotherapy, radiation therapy, and targeted therapies. While these treatments have improved survival rates, they are often associated with significant side effects and the development of resistance. Liver cancer is the sixth most common cancer and the third leading cause of cancer-related deaths worldwide, with approximately 905,000 new cases and 830,000 deaths annually. Hepatocellular carcinoma (HCC) is the most prevalent type, often diagnosed at an advanced stage, resulting in limited treatment efficacy and high mortality. Treatment options for liver cancer include surgical resection, liver transplantation, ablation, transarterial chemoembolization (TACE), systemic chemotherapy, and targeted therapies such as sorafenib and Lenvatinib. Despite these options, the prognosis remains poor due to the aggressive nature of the disease and frequent recurrence. The high mortality and prevalence of colon and liver cancers highlight the urgent need for more effective and less toxic treatment options. Novel molecular targets present a promising avenue for addressing these unmet medical needs by providing more precise and personalized therapeutic strategies. Recent advancements in molecular biology and high-throughput technologies have facilitated the discovery of new molecular targets involved in cancer pathogenesis. Understanding these targets' roles in colon and liver cancer progression can lead to the development of innovative therapies that specifically target cancer cells while sparing normal tissues. Targeting novel molecular targets can improve treatment outcomes by overcoming resistance to current therapies, reducing side effects, and enhancing the efficacy of existing treatments. This approach can lead to better patient survival rates and quality of life.
This Research Topic aims to advance the understanding and treatment of colon, lung, and liver cancers by focusing on several key objectives. First, it seeks to identify and characterize novel molecular targets specific to these cancers, elucidating their biological and molecular mechanisms of action. This includes exploring the therapeutic potential and development of new drugs that target these molecules and assessing their efficacy and safety through rigorous preclinical and clinical studies. The Research Topic will also delve into the pathways and interactions involving these novel targets, aiming to understand how their modulation can disrupt cancer progression and enhance patient outcomes. Additionally, it will address mechanisms of resistance to current therapies and investigate how novel targets can overcome these challenges. The development and validation of biomarkers based on these targets for early detection and prognostic assessment will also be a focus. Case studies and clinical trials highlighting the successes and obstacles encountered in targeting these novel targets will be presented, alongside discussions on the real-world application and integration of these therapies into clinical practice. Finally, the Research Topic will identify emerging trends and propose future research directions, aiming to drive breakthroughs in the field of cancer therapy.
This Research Topic welcomes researchers, scientists, and experts to contribute to a collection focused on novel molecular targets in colon, lung, and liver cancers even other types of cancers.
Submissions should address one or more of the following themes:
• Identification and characterization of novel targets specific to colon, lung, and liver cancer cells and understanding the biological and molecular mechanisms driving the expression and function of these targets.
• Therapeutic potential and drug development of new drugs targeting these novel molecules and assessing the efficacy and safety of these novel therapies through preclinical and clinical studies.
• To elucidate the pathways and interactions these novel targets are involved in and understand how targeting these molecules can disrupt cancer progression and survival.
• To identify mechanisms of resistance to current therapies and how novel targets can overcome these challenges.
• To develop and validate biomarkers based on novel molecular targets for early detection of colon and liver cancers.
• To evaluate the prognostic value of these biomarkers in predicting patient outcomes and treatment responses.
• To present case studies and clinical trials that highlight the success and challenges of targeting novel molecular targets in colon, lung, and liver cancer patients.
• To discuss real-world application and integration of these therapies into clinical practice.
• To identify emerging trends in the discovery and application of novel molecular targets and propose future research directions and potential breakthroughs in the field of colon and liver cancer therapy.
We encourage original research articles, reviews, case reports, and technical notes that contribute to the Research Topic "Novel Molecular Targets in Cancer Therapy".